Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines
Open Access
- 1 May 2008
- journal article
- research article
- Published by Elsevier in Laboratory Investigation
- Vol. 88 (5) , 491-503
- https://doi.org/10.1038/labinvest.2008.19
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cellsBritish Journal of Cancer, 2007
- Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patientsBritish Journal of Cancer, 2007
- A Comprehensive Analysis of Common Copy-Number Variations in the Human GenomeAmerican Journal of Human Genetics, 2007
- Genomic and transcriptional aberrations linked to breast cancer pathophysiologiesPublished by Elsevier ,2006
- Novel patterns of genome rearrangement and their association with survival in breast cancerGenome Research, 2006
- A collection of breast cancer cell lines for the study of functionally distinct cancer subtypesCancer Cell, 2006
- Global variation in copy number in the human genomeNature, 2006
- Regulation of Survivin by ErbB2 Signaling: Therapeutic Implications for ErbB2-Overexpressing Breast CancersCancer Research, 2006
- A multiplex PCR predictor for aCGH success of FFPE samplesBritish Journal of Cancer, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005